MSB0254

MSB0254 is a high affinity humanized antibody against VEGFR2, designed to inhibit tumor angiogenesis. MSB0254 was generated using the Company’s in-house antibody discovery platform. VEGFR-2 is overexpressed in neovascular endothelial cells in many tumors. VEGFR-2 pathway controls vascular permeability, survival and migration of the neovascular endothelial cells. VEGFR-2 is a clinically validated target in various tumor types including gastric cancer, non-small cell lung cancer and colorectal cancer. We have completed the Phase I dose escalation study and determined RP2D dose. Given proven activity of anti-VEGFR2 antibody in neovascular dependent tumors and observed synergy with other anti-tumor agents, we plan to use MSB0254 as the combination partner for our proprietary oncology assets.

Scientific Publications：

2021 CSCO Poster.pdf